Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

33.00

Mkt cap

1.9B

Volume

328K

High

33.18

P/E Ratio

15.56

52-wk high

41.61

Low

32.42

Div yield

N/A

52-wk low

27.14

Scorpion Capital has received an interim response from the FDA regarding their petition to withdraw approval of Harmony Biosciences' drug Wakix. The FDA has stated that the petition raises complex issues requiring extensive review and analysis. The final decision is expected within two weeks.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 7:50 pm

Mizuho analyst Graig Suvannavejh has maintained a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and kept the price target at $54.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 2:22 pm

Harmony Biosciences (NASDAQ:HRMY) has received 9 analyst ratings in the last quarter, with 6 being bullish, 3 somewhat bullish, and none being bearish or indifferent. The average 12-month price target for the company is $63.67, a decrease of 3.05% from the previous average of $65.67.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 9:00 pm

Harmony Biosciences has been granted Orphan Drug designation for Pitolisant, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 1:13 pm

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia (IH).

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 12:07 pm

Berenberg analyst Caroline Palomeque has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 9:53 am

Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $54.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:39 pm

The U.S. Patent and Trademark Office has denied a petition for reexamination of a patent covering the active ingredient in Wakix (Pitolisant), a product of Harmony Biosciences. This decision is favorable for Harmony Biosciences.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:06 pm

Harmony Biosciences (NASDAQ:HRMY) has received positive analyst ratings in the last quarter, with 6 bullish and 4 somewhat bullish ratings. The average 12-month price target for the company is $66.3, an increase of 0.96% from the previous average of $65.67.

Portfolio Pulse from Benzinga Insights

August 22, 2023 | 6:00 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.